NASDAQ:ME 23andMe (ME) Stock Price, News & Analysis $0.31 +0.01 (+1.91%) (As of 08/30/2024 04:00 PM ET) Add Compare Share Share Today's Range$0.31▼$0.3250-Day Range$0.31▼$0.5152-Week Range$0.30▼$1.25Volume929,900 shsAverage Volume2.85 million shsMarket Capitalization$154.38 millionP/E RatioN/ADividend YieldN/APrice Target$0.47 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get 23andMe alerts: Email Address 23andMe MarketRank™ Stock AnalysisAnalyst RatingReduce1.50 Rating ScoreUpside/Downside49.3% Upside$0.47 Price TargetShort InterestBearish6.27% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.14Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.12 out of 5 starsMedical Sector808th out of 933 stocksPharmaceutical Preparations Industry382nd out of 440 stocks 2.8 Analyst's Opinion Consensus Rating23andMe has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst Coverage23andMe has only been the subject of 1 research reports in the past 90 days.Read more about 23andMe's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.27% of the float of 23andMe has been sold short.Short Interest Ratio / Days to Cover23andMe has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in 23andMe has recently increased by 29.82%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend Yield23andMe does not currently pay a dividend.Dividend Growth23andMe does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ME. Previous Next 2.9 News and Social Media Coverage News Sentiment23andMe has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for 23andMe this week, compared to 7 articles on an average week.Search Interest7 people have searched for ME on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.MarketBeat Follows4 people have added 23andMe to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 23andMe insiders have not sold or bought any company stock.Percentage Held by Insiders27.55% of the stock of 23andMe is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 36.10% of the stock of 23andMe is held by institutions.Read more about 23andMe's insider trading history. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of 23andMe is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 23andMe is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio23andMe has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about 23andMe's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024 About 23andMe Stock (NASDAQ:ME)23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.Read More ME Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ME Stock News HeadlinesAugust 31 at 10:11 PM | ca.finance.yahoo.comME Jan 2025 7.000 callAugust 30, 2024 | msn.com"Nobody Ever Told Them That Vital Bit Of Info": People Who Took DNA Tests Are Sharing The Completely Shocking Truths They Have Discovered About ThemselvesSeptember 3, 2024 | Monument Traders Alliance (Ad)FREE Daily Profits Live Open HouseOver the past year, members of Millionaire trader Nate Bear's Daily Profits Live chatroom have had 62 opportunities to DOUBLE their money... Now it's YOUR CHANCE to hunt MASSIVE gains like these with a professional trader for an ENTIRE WEEK... 100% FREE!August 29, 2024 | msn.comWhy Affirm Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving PremarketAugust 29, 2024 | msn.comMy private data’s probably out there, but I’m not worried about itAugust 29, 2024 | msn.comTelegram CEO Pavel Durov says he had over 100 kids. The problem with anonymous sperm donation.August 29, 2024 | yahoo.comPeople Are Revealing The Family Scandals That Destroyed Marriages, Shattered Identities, And Gave The Employees Of 23andMe A Dang HeadacheAugust 28, 2024 | globenewswire.comLemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership ProgramSeptember 3, 2024 | Monument Traders Alliance (Ad)FREE Daily Profits Live Open HouseOver the past year, members of Millionaire trader Nate Bear's Daily Profits Live chatroom have had 62 opportunities to DOUBLE their money... Now it's YOUR CHANCE to hunt MASSIVE gains like these with a professional trader for an ENTIRE WEEK... 100% FREE!August 20, 2024 | ca.style.yahoo.comAmazon reviewers call the 23andMe DNA kit the 'gift of the year' — and it's 30% offAugust 13, 2024 | bizjournals.comGenetic data-rich spit kits were supposed to fuel 23andMe deals. Now the company's exiting drug discoveryAugust 9, 2024 | seekingalpha.com23andMe Holding Co. (ME) Q1 2025 Earnings Call TranscriptAugust 8, 2024 | investorplace.comME Stock Earnings: 23andMe Holding Beats EPS, Misses Revenue for Q1 2025August 8, 2024 | globenewswire.com23andMe Reports First Quarter Fiscal 2025 Financial ResultsAugust 7, 2024 | globenewswire.comDirect-to-Consumer (DTC) Genetic Testing Business Report 2023-2030 with Focus on 80+ Players Including 23andMe, Ancestry.com, Chengdu 23Mofang Biotechnology, and DirectLabsAugust 4, 2024 | marketwatch.com23andMe Says CEO's Offer to Go Private is Insufficient, Seeks Third PartiesAugust 3, 2024 | finance.yahoo.com23andMe board rejects CEO Wojcicki’s take-private proposalAugust 3, 2024 | msn.com23andMe says CEO’s take-private bid is insufficientSee More Headlines Receive ME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 23andMe and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/03/2024Next Earnings (Estimated)11/13/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ME CUSIPN/A CIK1804591 Webvgacquisition.com Phone650-938-6300FaxN/AEmployees770Year FoundedN/APrice Target and Rating Average Stock Price Target$0.47 High Stock Price Target$0.47 Low Stock Price Target$0.47 Potential Upside/Downside+49.3%Consensus RatingReduce Rating Score (0-4)1.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-666,700,000.00 Net Margins-317.03% Pretax Margin-316.99% Return on Equity-83.22% Return on Assets-51.12% Debt Debt-to-Equity RatioN/A Current Ratio1.52 Quick Ratio1.43 Sales & Book Value Annual Sales$219.64 million Price / Sales0.70 Cash Flow$0.15 per share Price / Cash Flow2.13 Book Value$0.38 per share Price / Book0.83Miscellaneous Outstanding Shares490,260,000Free Float355,191,000Market Cap$154.38 million OptionableNot Optionable Beta1.19 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMs. Anne WojcickiCo-Founder, CEO, President & Chair of the BoardMr. Joseph Selsavage (Age 61)Interim CFO & Accounting Officer Comp: $574.56kMr. Eli FryVice President of OperationsMr. Guy ChayounVP, Interim General Counsel & Corporate SecretaryMs. Katie Watson (Age 46)Vice President of Communications Mr. Jonathan WardChief Marketing OfficerMr. Reza Afkhami M.B.A.Chief Corporate Development OfficerMs. Savita PillaiVice President of PeopleDr. Jennifer Low (Age 55)Head of Therapeutics Development Mr. Kent Hillyer (Age 56)Vice President of Consumer Operations More ExecutivesKey CompetitorsVoltaNYSE:VLTABeauty HealthNASDAQ:SKINEmbark TechnologyNASDAQ:EMBKHolleyNYSE:HLLYOppFiNYSE:OPFIView All CompetitorsInsiders & InstitutionsPoint72 Asia Singapore Pte. Ltd.Bought 518,298 shares on 8/15/2024Ownership: 0.106%AQR Capital Management LLCBought 263,468 shares on 8/15/2024Ownership: 0.091%Point72 DIFC LtdBought 110,061 shares on 8/14/2024Ownership: 0.022%Vanguard Personalized Indexing Management LLCBought 71,204 shares on 8/12/2024Ownership: 0.018%Renaissance Technologies LLCSold 621,382 shares on 8/9/2024Ownership: 0.862%View All Insider TransactionsView All Institutional Transactions ME Stock Analysis - Frequently Asked Questions How have ME shares performed this year? 23andMe's stock was trading at $0.9135 at the beginning of the year. Since then, ME stock has decreased by 65.5% and is now trading at $0.3149. View the best growth stocks for 2024 here. How were 23andMe's earnings last quarter? 23andMe Holding Co. (NASDAQ:ME) released its earnings results on Thursday, August, 8th. The company reported ($0.14) EPS for the quarter. The business earned $40.41 million during the quarter, compared to the consensus estimate of $50.30 million. 23andMe had a negative trailing twelve-month return on equity of 83.22% and a negative net margin of 317.03%. Who are 23andMe's major shareholders? 23andMe's top institutional shareholders include Renaissance Technologies LLC (0.86%), Point72 Asia Singapore Pte. Ltd. (0.11%), AQR Capital Management LLC (0.09%) and Levin Capital Strategies L.P. (0.03%). Insiders that own company stock include Kathy L Hibbs, William G Richards and Kenneth J Hillan. View institutional ownership trends. How do I buy shares of 23andMe? Shares of ME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ME) was last updated on 9/3/2024 by MarketBeat.com Staff From Our PartnersFirst Disruption to $martphones in 15 Years 🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredFREE Daily Profits Live Open HouseOver the past year, members of Millionaire trader Nate Bear's Daily Profits Live chatroom have had 62 opportun...Monument Traders Alliance | SponsoredAmazon coin set to soar 25X – starting September 23rdChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredKamala? Trump? _______? Think again. This play has delivered an annualized average gain of nearly 50% in just three months time… before every singl...The Freeport Society | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWall St. Icon: Looming Financial Tsunami will Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event will hit the American...InvestorPlace | SponsoredThe only AI company to buyThe AI boom is just getting started. And the real wealth has still to be made…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 23andMe Holding Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share 23andMe With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ME Stock Alerts